English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/82323
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorSánchez-Pérez, Isabel-
dc.contributor.authorManguan-García, Cristina-
dc.contributor.authorMenacho-Márquez, Mauricio-
dc.contributor.authorMurguía, José Ramón-
dc.contributor.authorPerona Abellón, Rosario-
dc.date.accessioned2013-09-18T11:18:22Z-
dc.date.available2013-09-18T11:18:22Z-
dc.date.issued2009-
dc.identifierdoi: 10.1016/j.canlet.2008.08.026-
dc.identifierissn: 0304-3835-
dc.identifiere-issn: 1872-7980-
dc.identifier.citationCancer Letters 273(2): 281-291 (2009)-
dc.identifier.urihttp://hdl.handle.net/10261/82323-
dc.description.abstractRadio and chemotherapy are the election options besides surgical resection, in cancer treatment. However, resistance to chemotherapy limits the effectiveness of therapy in the clinic. An improved knowledge of the mechanisms underlying the resistance to treatment would generate new therapeutic strategies. Genetic suppressor elements (GSEs) are short, biologically active, cDNA fragments that interfere with the function of their cognate gene. By selection of genetic suppressor elements (GSEs) conferring resistance to cisplatin, we identified the GSE11, that corresponds to the hCCR4/CNOT6 gene that mediates cellular sensitivity to the drug. Expression of GSE11-hCCR4 reduces hCCR4 protein levels in cells. Targeting hCCR4 with GSE11 or with siRNA, decreases sensitivity of mammalian cells to DNA-damaging agents. Overexpression of hCCR4 targets Chk2 following exposure to cisplatin, without interfering with the upstream ATM/ATR pathway, however histone γH2AX is strongly phosphorylated in these cells compared to control cells. Our results uncover a new function for a human protein involved in chemotherapy response. This finding introduces a new pharmacological target in the treatment of solid tumours.-
dc.description.sponsorshipThis work was supported by grants 05/1305, 05/0834, and 06/0042 from Fondo de Investigación Sanitaria and from Mutua Madrileña Foundation. I.S.-P. and J.R.M. are in receipt of career development awards from the Ramón y Cajal program funded by the Spanish Ministerio de Educación y Ciencia.-
dc.language.isoeng-
dc.publisherElsevier-
dc.rightsclosedAccess-
dc.titlehCCR4/cNOT6 targets DNA-damage response proteins-
dc.typeartículo-
dc.identifier.doi10.1016/j.canlet.2008.08.026-
dc.date.updated2013-09-18T11:18:22Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBMCP) Artículos
(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.